Drug Trial Radar · NCT06514001
A Study of AMDX-2011P in Participants With Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Mar 7, 2025
Primary completion
Jul 2027
Study completion Aug 2027
Sponsor
- Lead sponsor
- Amydis Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess safety, tolerability, plasma pharmacokinetics and biologic activity of a single intravenous dose of AMDX-2011P in participants with Alzheimer's Disease (AD).
Conditions
- Alzheimer Disease
Interventions
AMDX-2011PDrug
AMDX-2011P single bolus injection intravenous for diagnostic review
Primary outcomes
What the sponsor says the trial is designed to measure.
- AMDX-2011P Adverse Events ProfileTime frame: 8 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Associated Retina Consultants
Phoenix, Arizona · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.